Aeglea BioTherapeutics to Release Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

  • George Diaz

Press/Media

Period4 Apr 2019

Media coverage

1

Media coverage

  • TitleAeglea BioTherapeutics to Release Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
    Media name/outletWireless News(Close-up Media)
    Country/TerritoryUnited States
    Date4/04/19
    PersonsGeorge Diaz